GlobeNewswire

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor

Share

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor

  • New patent granted in the United States by the USPTO protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035
     
  • This patent strengthens the protection of lanifibranor in the United States

             
Daix (France), August 20, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the United States Patent and Trademark Office (USPTO) granted a new patent on August 20, 2019 that protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035.

This new patent further strenghens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate, in the United States, which already comprised a New Chemical Entity (NCE) patent and a patent protecting the use of lanifibranor in several diseases including non-alcoholic steatohepatitis (“NASH”).

Pierre Broqua, Ph.D., Chief Scientific Officer and cofounder of Inventiva, stated: “This new patent represents an important milestone in the development of lanifibranor for the treatment of fibrotic diseases, particularly NASH, and confirms the innovative approach that we are pursuing in this treatment area. It is an additional positive news for our lead drug candidate after the FDA’s decision in May to lift the target class clinical hold for lanifibranor, and the significant recent progress in patient enrollment in our NATIVE Phase IIb clinical study in NASH.”


About lanifibranor

Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial metabolic changes in the body by activating all three peroxisome proliferator activated receptor (“PPAR”) isoforms, which are well characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan PPAR agonist in clinical development. Inventiva believes that lanifibranor’s moderate and balanced pan PPAR binding profile contributes to the favorable safety and tolerability profile that has been observed in clinical trials and pre clinical studies to date.

Inventiva is currently evaluating lanifibranor in a Phase IIb clinical trial for the treatment of non-alcoholic steatohepatitis (“NASH”), a common and progressive chronic liver disease, for which there is currently no approved therapy.


About Inventiva  

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates – lanifibranor and odiparcil – in non-alcoholic steatohepatitis (“NASH”) and mucopolysaccharidosis (“MPS”), respectively, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease. Inventiva is currently evaluating lanifibranor in a Phase IIb clinical trial for the treatment of this disease for which there are currently no approved therapies.

Inventiva is also developing odiparcil, a second clinical‑stage asset, for the treatment of patients with MPS, a group of rare genetic disorders. The Company is currently investigating odiparcil in a Phase IIa clinical trial for the treatment of patients with the MPS VI subtype.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. The Company has established two strategic partnerships with AbbVie and Boehringer Ingelheim in the areas of autoimmune diseases and idiopathic pulmonary fibrosis (“IPF”) respectively. AbbVie has started the clinical development phase of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. Both collaborations entitle Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the partnerships.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology a well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, around 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012). www.inventivapharma.com  


Contacts  

Inventiva
Frédéric Cren
Chairman & CEO
info@inventivapharma.com
+33 3 80 44 75 00


Brunswick Group
Yannick Tetzlaff / Tristan Roquet Montegon
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83


LifeSci Advisors

Monique Kosse

Investor relations

monique@lifesciadvisors.com

+1 212 915 3820


Important Notice

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence" filed with the Autorité des Marchés Financiers on April 12, 2019 under n° R.19-006 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

CORRECTION: Sampo plc: Managers’ Transactions (Thorsrud)19.9.2019 14:45:00 CESTPress release

SAMPO PLC MANAGERS’ TRANSACTIONS 19 September 2019 at 3:45 pm CORRECTION: Sampo plc: Managers’ Transactions (Thorsrud) Correction to Sampo plc’s (business code 0142213-3) stock exchange release regarding Managers’ Transactions on 17 September 2019 at 3:30 pm. Due to a technical error, the number of shares was misreported. Below is the corrected notification. ____________________________________________ Person subject to the notification requirement Name: Thorsrud, Morten Position: Other senior manager Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: AMENDMENT Reference number: 743700UF3RL386WIDA22_20190917122413_6 Amendment comment: Due to a technical error, the number of shares was misreported on 17 September 2019. ____________________________________________ Transaction date: 2019-09-13 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1): Volume:

CORRECTION: Sampo plc: Managers’ Transactions (Magnusson)19.9.2019 14:45:00 CESTPress release

SAMPO PLC MANAGERS’ TRANSACTIONS 19 September 2019 at 3:45 pm CORRECTION: Sampo plc: Managers’ Transactions (Magnusson) Correction to Sampo plc’s (business code 0142213-3) stock exchange release regarding Managers’ Transactions on 17 September 2019 at 3:35 pm. Due to a technical error, the number of shares was misreported. Below is the corrected notification. ____________________________________________ Person subject to the notification requirement Name: Magnusson, Torbjörn Position: Other senior manager Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: AMENDMENT Reference number: 743700UF3RL386WIDA22_20190917121931_9 Amendment comment: Due to a technical error, the number of shares was misreported on 17 September 2019. ____________________________________________ Transaction date: 2019-09-13 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1): Vol

CORRECTION: Sampo plc: Managers’ Transactions (Martinsen)19.9.2019 14:45:00 CESTPress release

SAMPO PLC MANAGERS’ TRANSACTIONS 19 September 2019 at 3:45 pm CORRECTION: Sampo plc: Managers’ Transactions (Martinsen) Correction to Sampo plc’s (business code 0142213-3) stock exchange release regarding Managers’ Transactions on 17 September 2019 at 3:35 pm. Due to a technical error, the number of shares was misreported. Below is the corrected notification. ____________________________________________ Person subject to the notification requirement Name: Martinsen, Ivar Position: Other senior manager Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: AMENDMENT Reference number: 743700UF3RL386WIDA22_20190917122147_10 Amendment comment: Due to a technical error, the number of shares was misreported on 17 September 2019. ____________________________________________ Transaction date: 2019-09-13 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1): Volume

CORRECTION: Sampo plc: Managers’ Transactions (Alsaker)19.9.2019 14:45:00 CESTPress release

SAMPO PLC MANAGERS’ TRANSACTIONS 19 September 2019 at 3:45 pm CORRECTION: Sampo plc: Managers’ Transactions (Alsaker) Correction to Sampo plc’s (business code 0142213-3) stock exchange release regarding Managers’ Transactions on 17 September 2019 at 3:35 pm. Due to a technical error, the number of shares was misreported. Below is the corrected notification. ____________________________________________ Person subject to the notification requirement Name: Alsaker, Knut Arne Position: Other senior manager Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: AMENDMENT Reference number: 743700UF3RL386WIDA22_20190917121748_4 Amendment comment: Due to a technical error, the number of shares was misreported on 17 September 2019. ____________________________________________ Transaction date: 2019-09-13 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1): Volume

CORRECTION: Sampo plc: Managers’ Transactions (Wennerklint)19.9.2019 14:45:00 CESTPress release

SAMPO PLC MANAGERS’ TRANSACTIONS 19 September 2019 at 3:45 pm CORRECTION: Sampo plc: Managers’ Transactions (Wennerklint) Correction to Sampo plc’s (business code 0142213-3) stock exchange release regarding Managers’ Transactions on 17 September 2019 at 3:30 pm. Due to a technical error, the number of shares was misreported. Below is the corrected notification. ____________________________________________ Person subject to the notification requirement Name: Wennerklint, Ricard Position: Other senior manager Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: AMENDMENT Reference number: 743700UF3RL386WIDA22_20190917122500_13 Amendment comment: Due to a technical error, the number of shares was misreported on 17 September 2019. ____________________________________________ Transaction date: 2019-09-13 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1):